Association of clinical and genetic risk factors with management of dyslipidaemia: analysis of repeated cross-sectional studies in the general population of Lausanne, Switzerland

Objectives To assess the importance of clinical and genetic factors in management of dyslipidaemia in the general population. Design Repeated cross-sectional studies (2003–2006; 2009–2012 and 2014–2017) from a population-based cohort. Setting Single centre in Lausanne, Switzerland. Participants 617 (42.6% women, mean±SD: 61.6±8.5 years), 844 (48.5% women, 64.5±8.8 years) and 798 (50.3% women, 68.1±9.2) participants of the baseline, first and second follow-ups receiving any type of lipid-lowering drug. Participants were excluded if they had missing information regarding lipid levels, covariates or genetic data. Primary and secondary outcome measures Management of dyslipidaemia was assessed according to European or Swiss guidelines. Genetic risk scores (GRSs) for lipid levels were computed based on the existing literature. Results Prevalence of adequately controlled dyslipidaemia was 52%, 45% and 46% at baseline, first and second follow-ups, respectively. On multivariable analysis, when compared with intermediate or low-risk individuals, participants at very high cardiovascular risk had an OR for dyslipidaemia control of 0.11 (95% CI: 0.06 to 0.18), 0.12 (0.08 to 0.19) and 0.38 (0.25 to 0.59) at baseline, first and second follow-ups, respectively. Use of newer generation or higher potency statins was associated with better control: OR of 1.90 (1.18 to 3.05) and 3.62 (1.65 to 7.92) for second and third generations compared with first in the first follow-up, with the corresponding values in the second follow-up being 1.90 (1.08 to 3.36) and 2.18 (1.05 to 4.51). No differences in GRSs were found between controlled and inadequately controlled subjects. Similar findings were obtained using Swiss guidelines. Conclusion Management of dyslipidaemia is suboptimal in Switzerland. The effectiveness of high potency statins is hampered by low posology. The use of GRSs in the management of dyslipidaemia is not recommended.

[1]  ESC / EAS Guidelines for the Treatment of Dyslipidemias: Lipid Modification to Reduce Cardiovascular Risk , 2020, Digital Doctor.

[2]  S. Srivatsa,et al.  Role of Statins in the Primary Prevention of Atherosclerotic Cardiovascular Disease and Mortality in the Population with Mean Cholesterol in the Near-Optimal to Borderline High Range: A Systematic Review and Meta-Analysis , 2020, medRxiv.

[3]  A. Parkhomenko,et al.  EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. , 2020, European journal of preventive cardiology.

[4]  B. Nordestgaard,et al.  Proportion of High-Risk/Very High-Risk Patients in Europe with Low-Density Lipoprotein Cholesterol at Target According to European Guidelines: A Systematic Review , 2020, Advances in Therapy.

[5]  G. Hindricks,et al.  2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. , 2019, Atherosclerosis.

[6]  J. De Sutter,et al.  Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. , 2019, Atherosclerosis.

[7]  Mark Woodward,et al.  Sex Differences in the Prevalence of, and Trends in, Cardiovascular Risk Factors, Treatment, and Control in the United States, 2001 to 2016 , 2019, Circulation.

[8]  Hyunjin Oh,et al.  Evaluating the prevalence, awareness, and control of hypertension, diabetes, and dyslipidemia in Korea using the NHIS-NSC database , 2018, Medicine.

[9]  X. Pintó,et al.  Influence of 6 genetic variants on the efficacy of statins in patients with dyslipidemia , 2018, Journal of clinical laboratory analysis.

[10]  E. Argulian,et al.  Trends and disparities in statin use and low-density lipoprotein cholesterol levels among US patients with diabetes, 1999-2014. , 2018, Diabetes research and clinical practice.

[11]  P. Heuschmann,et al.  Control of cardiovascular risk factors and its determinants in the general population– findings from the STAAB cohort study , 2017, BMC Cardiovascular Disorders.

[12]  Samuel G. Johnson,et al.  Impact of Pharmacogenetics on Efficacy and Safety of Statin Therapy for Dyslipidemia , 2017, Pharmacotherapy.

[13]  W. Drygas,et al.  Changes in the prevalence, treatment, and control of hypercholesterolemia and other dyslipidemias over 10 years in Poland: the WOBASZ study. , 2016, Polskie Archiwum Medycyny Wewnetrznej.

[14]  G. Dinç,et al.  Determinants of prevalence, awareness, treatment and control of high LDL-C in Turkey , 2016, Anatolian journal of cardiology.

[15]  N. Rodondi,et al.  [Recommendations for management of dyslipidemia in 2016 in Switzerland]. , 2016, Revue medicale suisse.

[16]  Jennifer G. Robinson,et al.  Genetic Predisposition to Dyslipidemia and Risk of Preeclampsia. , 2015, American journal of hypertension.

[17]  Olle Melander,et al.  Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials , 2015, The Lancet.

[18]  Barry J. Davis,et al.  Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials , 2015, The Lancet.

[19]  Andrew D. Johnson,et al.  Gene-age interactions in blood pressure regulation: a large-scale investigation with the CHARGE, Global BPgen, and ICBP Consortia. , 2014, American journal of human genetics.

[20]  N. Rodondi,et al.  [Recommendations for management of dyslipidemia in 2014]. , 2014, Revue medicale suisse.

[21]  N. Wong.  Faculty Opinions recommendation of 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014 .

[22]  D. Wald,et al.  Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. , 2012, The American journal of medicine.

[23]  P. Ridker,et al.  Kinesin-Like Protein 6 (KIF6) Polymorphism and the Efficacy of Rosuvastatin in Primary Prevention , 2011, Circulation. Cardiovascular genetics.

[24]  M. Flather.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010 .

[25]  Inês Barroso,et al.  Genetic Variants Influencing Circulating Lipid Levels and Risk of Coronary Artery Disease , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[26]  Tanya M. Teslovich,et al.  Biological, Clinical, and Population Relevance of 95 Loci for Blood Lipids , 2010, Nature.

[27]  F. Paccaud,et al.  Predictive accuracy and usefulness of calibration of the ESC SCORE in Switzerland , 2008, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[28]  Thomas Mills,et al.  National Study of Physician Awareness and Adherence to Cardiovascular Disease Prevention Guidelines , 2005, Circulation.

[29]  Vincent Mooser,et al.  The CoLaus study: a population-based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and metabolic syndrome , 2008, BMC cardiovascular disorders.

[30]  L. Berthiaume,et al.  Wnt acylation: seeing is believing. , 2014, Nature chemical biology.

[31]  Jennifer G. Robinson,et al.  Reprint: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. , 2013, Journal of the American Pharmacists Association : JAPhA.

[32]  O. Delaneau,et al.  Supplementary Information for ‘ Improved whole chromosome phasing for disease and population genetic studies ’ , 2012 .